iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc. (ITOS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
itos · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for iTeos Therapeutics, Inc. (ITOS) measures how much investors pay for each dollar of the company's trailing earnings. ITOS's current PE ratio of N/A is calculated by dividing its stock price of $10.15 by its TTM earnings per share of -$3.61.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2018 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
iTeos Therapeutics, Inc.You ITOS | $449M | N/A | — | -$3.61 |
 Big Cypress Acquisition Corp. BCYP | $425M | 12.28x | — | $0.69 |
 Checkpoint Therapeutics, Inc. CKPT | $368M | N/A | — | -$1.42 |
 Climb Bio, Inc. CLYM | $734M | N/A | — | -$0.88 |
 G1 Therapeutics, Inc. GTHX | $378M | N/A | — | -$0.93 |
 Invivyd, Inc. IVVD | $135M | N/A | — | -$0.30 |
 Orchard Therapeutics plc ORTX | $380M | N/A | — | -$0.62 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-3.32 | — | |
2023-12-31 FY2023 | — | $-3.15 | — | |
2022-12-31 FY2022 | 7.18x | $2.72 | -5.9% | |
2021-12-31 FY2021 | 7.64x | $6.10 | — | |
2020-12-31 FY2020 | — | $-1.09 | — | |
2019-12-31 FY2019 | — | $-2.27 | — | |
2018-12-31 FY2018 | — | $-2.40 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for iTeos Therapeutics, Inc. (ITOS) measures how much investors pay for each dollar of the company's trailing earnings. ITOS's current PE ratio of N/A is calculated by dividing its stock price of $10.15 by its TTM earnings per share of -$3.61.
Frequently asked questions
ITOS pe ratio · 6 questionsITOS's current PE ratio is N/A as of 2026-06-09, based on a stock price of $10.15 and TTM EPS of -$3.61. Data sourced from Financial Modeling Prep via ITOS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · iTeos Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09